" Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease " Disease
Conditions: Change in Albumin to Creatinine Ratio and Glomerular Filtration Rate; Progression of Kidney Failure and or All-cause Mortality Intervention: Other: no intervention study Sponsors: Soutien aux Actions contre les Maladies du Globule Rouge; Novartis Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2022 Category: Research Source Type: clinical trials
Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial
This study is a randomized, double-blind, three-group-parallel, placebo-controlled clinical trial. One hundred and twenty eligible IgA nephropathy patients at risk of progression will be randomly divided into the artesunate 100-mg group, artesunate 50-mg group, and placebo group. Changes in proteinuria and renal function will be measured 6 months after the intervention. The levels of Gd-IgA1 and anti-Gd-IgA1 in the patient ’s blood will also be tested to explore the possible immune mechanisms.DiscussionClinical evidence supporting artesunate treatment of IgA nephropathy is currently lacking, and we expect that the result...
Source: Trials - May 25, 2022 Category: Research Source Type: clinical trials
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
Condition: Proteinuria Intervention: Drug: ALXN1720 Sponsor: Alexion Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 6, 2022 Category: Research Source Type: clinical trials
